TG Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on March 20, 2020. The report details the launch of an "at the market" equity offering program to raise capital through the sale of common stock.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of a new securities offering.
Material Changes
The primary material event reported is the execution of an At Market Sales Agreement dated March 20, 2020. Under this agreement, the Company may sell shares of its common stock through three agents: Jefferies LLC, Cantor Fitzgerald & Co., and B. Riley FBR, Inc.
Offering Terms and Management Commentary
- Offering Type: At the market offering (Rule 415) of common stock with a par value of $0.001 per share.
- Agents: Jefferies LLC, Cantor Fitzgerald & Co., and B. Riley FBR, Inc.
- Commission: The Company will pay the agents a commission of up to 3.0% of the gross proceeds from any shares sold.
- Flexibility: The Company is not obligated to sell any shares and will determine the number of shares, dates, and minimum price parameters for each sale.
- Legal Counsel: Alston & Bird LLP provided an opinion on the offering, filed as Exhibit 5.1.
Investor Verification Checklist
- Verify the total number of shares authorized for sale under the Sales Agreement (not specified in this summary text).
- Monitor future filings for actual sales volumes and gross proceeds generated under this program.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination clauses and additional covenants.
- Check subsequent 8-K filings for any minimum price floors set by the Company for share sales.